AR002018A1 - Derivado de benzotiepina opticamente activo; metodo para producirlo; compuesto opticamente activo de uso en dicho metodo; promotor deosteogenesis, agente para prevenir o tratar enfermedades del hueso, promotor para el tratamiento de la fractura de hueso, metodo de tratamiento y - Google Patents
Derivado de benzotiepina opticamente activo; metodo para producirlo; compuesto opticamente activo de uso en dicho metodo; promotor deosteogenesis, agente para prevenir o tratar enfermedades del hueso, promotor para el tratamiento de la fractura de hueso, metodo de tratamiento yInfo
- Publication number
- AR002018A1 AR002018A1 ARP950100805A AR10080595A AR002018A1 AR 002018 A1 AR002018 A1 AR 002018A1 AR P950100805 A ARP950100805 A AR P950100805A AR 10080595 A AR10080595 A AR 10080595A AR 002018 A1 AR002018 A1 AR 002018A1
- Authority
- AR
- Argentina
- Prior art keywords
- promoter
- optically active
- bone
- treatment
- formula
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 6
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 208000020084 Bone disease Diseases 0.000 title abstract 4
- 208000010392 Bone Fractures Diseases 0.000 title abstract 3
- 230000011164 ossification Effects 0.000 abstract 4
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 230000001737 promoting effect Effects 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- NIGNBCLEMMGDQP-UHFFFAOYSA-N 1-benzothiepine Chemical class S1C=CC=CC2=CC=CC=C12 NIGNBCLEMMGDQP-UHFFFAOYSA-N 0.000 abstract 1
- 208000006386 Bone Resorption Diseases 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 125000003277 amino group Chemical group 0.000 abstract 1
- 210000000988 bone and bone Anatomy 0.000 abstract 1
- 230000024279 bone resorption Effects 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms
- C07F9/655363—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms the sulfur atom being part of a six-membered ring
- C07F9/655372—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms the sulfur atom being part of a six-membered ring condensed with carbocyclic rings or carbocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/67—Phosphorus compounds having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
- C07F9/657163—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms the ring phosphorus atom being bound to at least one carbon atom
- C07F9/657181—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms the ring phosphorus atom being bound to at least one carbon atom the ring phosphorus atom and, at least, one ring oxygen atom being part of a (thio)phosphonic acid derivative
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invención describe una droga clínicamente útil que demuestra acción directa sobre el hueso, para suprimir resorción de hueso, y promover laformación del hueso, el cual es un derivado de benzotiepina ópticamente activo representadopor la fórmula(I),en donde R representa un grupo alquilo inferior,R1 y R2 independientemente representan un grupo alquilo inferior, o pueden enlazarse entre sí para formar un anillo; y se encontró que este compuesto esinesperadamente muy útilclíni camente y particularmente óptimo en la actividad promotora de osteogénesis y absorbilidad oral. Se describe también un métodopara producir el compuesto ópticamente activo de la fórmula (I) haciendo reaccionar un compuesto ópticamenteactivo d e la fórmula (II), en donde R poseela misma definición mencionada precedentemente, o su derivado reactivo o sal en el grupo carboxilo, con un compuesto de la fórmula (III), en donde R1 y R2poseen las mismas definiciones iguales a lasmencionadas prec edentemente, o su derivado reactivo o sal en el grupo amino. Se proveen además, un promotor deosteogénesis, un agente profiláctico o agente terapéutico para las enfermedades del hueso, un promotor para el tratamiento de la fracturade hueso, un méto dopara promover osteogénesis, un método para prevenir o tratar enfermedades de hueso y un método promotor de tratamiento de fractura de hueso en un mamífero.Se describen composiciones farmacéuticas que comprenden al derivado de fórmula (I ).
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP32727594 | 1994-12-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR002018A1 true AR002018A1 (es) | 1998-01-07 |
Family
ID=18197308
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP950100805A AR002018A1 (es) | 1994-12-28 | 1995-12-28 | Derivado de benzotiepina opticamente activo; metodo para producirlo; compuesto opticamente activo de uso en dicho metodo; promotor deosteogenesis, agente para prevenir o tratar enfermedades del hueso, promotor para el tratamiento de la fractura de hueso, metodo de tratamiento y |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US6346521B1 (es) |
| EP (1) | EP0719782B1 (es) |
| KR (1) | KR960022542A (es) |
| CN (1) | CN1058718C (es) |
| AR (1) | AR002018A1 (es) |
| AT (1) | ATE202782T1 (es) |
| AU (1) | AU689004B2 (es) |
| BR (1) | BR9506098A (es) |
| CA (1) | CA2166152A1 (es) |
| DE (1) | DE69521595T2 (es) |
| DK (1) | DK0719782T3 (es) |
| ES (1) | ES2158034T3 (es) |
| FI (1) | FI956273A (es) |
| GR (1) | GR3036757T3 (es) |
| HU (1) | HUT74562A (es) |
| NO (1) | NO303641B1 (es) |
| NZ (1) | NZ280745A (es) |
| PT (1) | PT719782E (es) |
| RU (1) | RU2162083C2 (es) |
| TW (1) | TW403757B (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2221784A1 (en) * | 1995-06-05 | 1996-12-12 | Takeda Chemical Industries, Ltd. | Osteogenetic promoting pharmaceutical composition |
| US5910492A (en) * | 1995-06-05 | 1999-06-08 | Takeda Chemical Industries, Ltd. | Osteogenic promoting pharmaceutical composition |
| CA2226317A1 (en) * | 1995-07-24 | 1997-02-06 | Takeda Chemical Industries, Ltd. | Production of optically active benzothiepin salts |
| ID18079A (id) | 1996-08-26 | 1998-02-26 | Takeda Chemical Industries Ltd | Komposisi farmasi yang mengandung bahan pemercepat osteogenesis |
| CA2267930A1 (en) * | 1996-10-09 | 1998-04-16 | Nobuyuki Takechi | A method for producing a microparticle |
| CA2334815A1 (en) * | 1998-06-15 | 1999-12-23 | Haruhiko Makino | Composition for treating cartilage disease |
| US6355672B1 (en) | 1998-08-07 | 2002-03-12 | Takeda Chemical Industries, Ltd. | Benzothiepin derivatives, process for the preparation of the same and uses thereof |
| AR020158A1 (es) * | 1998-08-12 | 2002-04-10 | Takeda Chemical Industries Ltd | Mejorador del factor de induccion para la diferenciacion celular |
| EP1120122A1 (en) * | 1998-09-30 | 2001-08-01 | Takeda Chemical Industries, Ltd. | Bone repair materials/artificial bone compositions |
| EP1286984A2 (en) * | 2000-03-10 | 2003-03-05 | Pharmacia Corporation | Method for the preparation of tetrahydrobenzothiepines |
| WO2003007916A1 (en) * | 2001-07-17 | 2003-01-30 | Teva Pharmaceutical Industries Ltd. | Dosage forms for immediate gastric release of a calcium transport stimulator coupled with delayed gastric release of a bis-phosphonate |
| US20050026871A1 (en) * | 2002-07-17 | 2005-02-03 | Moshe Flashner-Barak | Method of increasing bioavailability of alendronate or other bis-phosphonate by predose administration of vitamin D derivative |
| EP1640010A1 (en) * | 2003-07-01 | 2006-03-29 | Astellas Pharma Inc. | Agent inducing increase in bone mass |
| CA2691681C (en) * | 2007-06-29 | 2015-12-01 | Kci Licensing Inc. | Activation of bone and cartilage formation |
| KR20110110183A (ko) | 2009-01-19 | 2011-10-06 | 다이이찌 산쿄 가부시키가이샤 | 헤테로 원자를 갖는 고리형 화합물 |
| BRPI1013988A2 (pt) | 2009-04-06 | 2016-04-05 | Daiichi Sankyo Co Ltd | composto, composição farmacêutica , e, uso de um composto ou um sal farmacologicamente aceitável do mesmo |
| KR20130065632A (ko) | 2010-04-28 | 2013-06-19 | 다이이찌 산쿄 가부시키가이샤 | ［５，６］복소 고리 화합물 |
| CA2922716C (en) | 2013-08-29 | 2021-10-12 | Kyoto Pharmaceutical Industries, Ltd. | Aromatic compound and use thereof in the treatment of disorders associated with bone metabolism |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5158943A (en) * | 1988-11-21 | 1992-10-27 | Takeda Chemical Industries, Ltd. | Sulfur-containing heterocyclic compounds |
| NZ231939A (en) | 1988-12-28 | 1991-07-26 | Takeda Chemical Industries Ltd | Benzothiopyran derivatives and medicaments |
| EP0460488B1 (en) * | 1990-05-30 | 2001-07-11 | Takeda Chemical Industries, Ltd. | Sulfur-containing heterocyclic compounds |
| JP3165866B2 (ja) * | 1990-06-06 | 2001-05-14 | 武田薬品工業株式会社 | 含硫黄複素環化合物 |
-
1995
- 1995-12-20 TW TW084113629A patent/TW403757B/zh not_active IP Right Cessation
- 1995-12-21 NZ NZ280745A patent/NZ280745A/en unknown
- 1995-12-22 DK DK95120444T patent/DK0719782T3/da active
- 1995-12-22 AT AT95120444T patent/ATE202782T1/de not_active IP Right Cessation
- 1995-12-22 EP EP95120444A patent/EP0719782B1/en not_active Expired - Lifetime
- 1995-12-22 PT PT95120444T patent/PT719782E/pt unknown
- 1995-12-22 DE DE69521595T patent/DE69521595T2/de not_active Expired - Fee Related
- 1995-12-22 AU AU40693/95A patent/AU689004B2/en not_active Ceased
- 1995-12-22 ES ES95120444T patent/ES2158034T3/es not_active Expired - Lifetime
- 1995-12-27 RU RU95122478/04A patent/RU2162083C2/ru active
- 1995-12-27 CA CA002166152A patent/CA2166152A1/en not_active Abandoned
- 1995-12-27 BR BR9506098A patent/BR9506098A/pt unknown
- 1995-12-27 NO NO955305A patent/NO303641B1/no not_active IP Right Cessation
- 1995-12-27 HU HU9503802A patent/HUT74562A/hu unknown
- 1995-12-27 FI FI956273A patent/FI956273A/fi unknown
- 1995-12-28 KR KR1019950061545A patent/KR960022542A/ko not_active Application Discontinuation
- 1995-12-28 AR ARP950100805A patent/AR002018A1/es unknown
- 1995-12-28 US US08/579,731 patent/US6346521B1/en not_active Expired - Fee Related
- 1995-12-28 CN CN95121715A patent/CN1058718C/zh not_active Expired - Fee Related
-
2000
- 2000-08-09 US US09/635,067 patent/US6632807B1/en not_active Expired - Fee Related
-
2001
- 2001-09-28 GR GR20010401614T patent/GR3036757T3/el not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| DE69521595D1 (de) | 2001-08-09 |
| KR960022542A (ko) | 1996-07-18 |
| CN1058718C (zh) | 2000-11-22 |
| FI956273A (fi) | 1996-06-29 |
| BR9506098A (pt) | 1997-12-23 |
| EP0719782A1 (en) | 1996-07-03 |
| US6632807B1 (en) | 2003-10-14 |
| US6346521B1 (en) | 2002-02-12 |
| HU9503802D0 (en) | 1996-02-28 |
| DK0719782T3 (da) | 2001-09-24 |
| HUT74562A (en) | 1997-01-28 |
| NZ280745A (en) | 1997-09-22 |
| RU2162083C2 (ru) | 2001-01-20 |
| NO955305D0 (no) | 1995-12-27 |
| PT719782E (pt) | 2001-10-31 |
| NO955305L (no) | 1996-07-01 |
| CA2166152A1 (en) | 1996-06-29 |
| NO303641B1 (no) | 1998-08-10 |
| FI956273A0 (fi) | 1995-12-27 |
| AU689004B2 (en) | 1998-03-19 |
| CN1131669A (zh) | 1996-09-25 |
| TW403757B (en) | 2000-09-01 |
| GR3036757T3 (en) | 2001-12-31 |
| ATE202782T1 (de) | 2001-07-15 |
| DE69521595T2 (de) | 2002-05-23 |
| ES2158034T3 (es) | 2001-09-01 |
| AU4069395A (en) | 1996-07-04 |
| EP0719782B1 (en) | 2001-07-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR002018A1 (es) | Derivado de benzotiepina opticamente activo; metodo para producirlo; compuesto opticamente activo de uso en dicho metodo; promotor deosteogenesis, agente para prevenir o tratar enfermedades del hueso, promotor para el tratamiento de la fractura de hueso, metodo de tratamiento y | |
| HUP0401192A2 (hu) | Fényérzékenyítő szer alkalmazása sebek kezelésére adható gyógyászati készítmény előállítására | |
| NO20053498L (no) | Derivater av aryl-quinaolin/aryl-2-amino-fenylmetanon som fremmer frigivelse av paratyroidhormon | |
| EA200700860A1 (ru) | (бифенил)карбоновые кислоты и их производные | |
| ATE355374T1 (de) | Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen | |
| SG154333A1 (en) | The use of substituted cyanopyrrolidines and combination preparations containing them for treating hyperlipidemia and associated diseases | |
| ATE219363T1 (de) | Lösliche prodrugs von paclitaxel | |
| ATE445405T1 (de) | Vorbeugung und behandlung von oxidativer-stress- erkrankungen mit verbindungen die den intrazellulären spiegel von glutathion oder phase-ii-entgiftungsenzymen erhöhen | |
| AR029150A1 (es) | Un derivado de piperidina, su empleo, un procedimiento para prepararlo y una composicin farmaceutica que lo comprende. | |
| MXPA04003245A (es) | Hidroxipropilaminas. | |
| LV12291A (lv) | Savienojums un farmaceitiskas kompozicijas ar triptazes aktivitates izmainam saistitu slimibu arstesanai | |
| ES2063146T3 (es) | Composiciones farmaceuticas que contienen acido n-(3,4-dimetoxicinamoil)-antranilico. | |
| DE69327328T2 (de) | Verwendund von norastemizol zur behandlung der allergischen rhinitis | |
| DE69125216D1 (de) | Aminoalkanesulfonsäurederivate und pharmazeutische Zusammensetzungen davon zur Prävention oder Behandlung von Herzerkrankungen | |
| ATE367387T1 (de) | Verwendung von oxindolderivaten zur behandlung von mit demenz in zusammenhang stehenden krankheiten, alzheimer-krankheit und mit glycogensynthasekinase-3 assoziierten leiden | |
| DE69834500D1 (de) | Xanthinderivative zur behandlung von hirnischämie | |
| ATE409028T1 (de) | Arzneien zur behandlung von nervenerkrankungen | |
| PL360492A1 (en) | Use of pamoic acid or one of its derivatives, or one of its analogues, for the preparation of a medicament for the treatment of diseases characterised by deposits of amyloid aggregates | |
| ATE161725T1 (de) | Verwendung von phosphatdiestern zur behandlung von erkrankungen der retina | |
| BR9205700A (pt) | Aperfeiçoamento em um processo para purificar e preservar fator IX derivado de plasma do sangue humano ou outra fonte, processos para a preparação de uma composição terapêutica, e para estabilizar fator IX, solução aquosa de fator IX parcialmente purificado, composição terapêutica e processo para tratar doença de christmas. | |
| AR008371A1 (es) | Una sal de adicion con acido de una 10-aminoalifatil-dibenz[b,f],oxepina, su empleo; procedimiento para su elaboracion, una 10-aminoalifatil-dibenz[b,f]oxepina, una preparacion farmaceutica que contiene dicha sal o dicha oxepina y un procedimiento para el tratamiento de enfermedades neurodegenerativ | |
| RU2007143434A (ru) | 4-анилино-3-хинолинкарбонитрилы, подходящие для лечения раковых заболеваний | |
| DE69400352D1 (de) | 3- oder 4-Glykosyloxybenzopyranderivat und dieses enthaltende antiallergisches Mittel | |
| DE60219680D1 (de) | Amin-1,2- und -1,3-diolverbindungen und deren verwendung zur behandlung von alzheimer-krankheit | |
| ATE247963T1 (de) | Medikament zur behandlung von glaukoma und ischämischer retinopathie |